Iovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors - IOVA News | RalliesIovance publishes corporate presentation highlighting Amtagvi TIL therapy rollout and pipeline expansion in solid tumors
I
IOVA• Pipeline expansion in solid tumors
- Pipeline focus remained on lifileucel in NSCLC, with a potential commercial launch targeted for 2H27.
Amtagvi rollout and commercial progress
- Iovance highlighted expanding commercialization of Amtagvi, citing about 2,000 commercial and clinical treatments to date.
- 2Q26 revenue ran more than 10% above guidance; year-over-year quarterly revenue growth was about 66%.
- Gross margin from cost of sales was 56% in 2Q26; cash totaled about USD 304 million as of June 30, 2026.
- Authorized treatment centers exceeded 95 across the U.S., Canada, Australia; more than 95% of addressable patients were within 200 miles of a center.
•
